PMID- 18307515
OWN - NLM
STAT- MEDLINE
DCOM- 20080512
LR  - 20211020
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 152
IP  - 1
DP  - 2008 Apr
TI  - Prevention of graft-versus-host disease by intrabone marrow injection of donor T 
      cells: involvement of bone marrow stromal cells.
PG  - 153-62
LID - 10.1111/j.1365-2249.2008.03615.x [doi]
AB  - We have developed a new and effective method for bone marrow transplantation 
      (BMT): bone marrow cells (BMCs) are injected directly into the bone marrow (BM) 
      cavity of recipient mice. The intrabone marrow injection of BMCs (IBM-BMT) 
      greatly facilitates the engraftment of donor-derived cells, and IBM-BMT can 
      attenuate graft-versus-host reaction (GVHR), in contrast to conventional 
      intravenous BMT (i.v.-BMT). Here, we examine the mechanisms underlying the 
      inhibitory effects of IBM-BMT on GVHR using animal models where GVHR is elicited. 
      Recipient mice (C57BL/6) were irradiated and splenic T cells (as donor lymphocyte 
      infusion: DLI) from major histocompatibility complex-disparate donors (BALB/c) 
      were injected directly into the BM cavity (IBM-DLI) or injected intravenously 
      (i.v.-DLI) along with IBM-BMT. The BM stromal cells (BMSCs) from these recipients 
      were collected and related cytokines were examined. The recipient mice that had 
      been treated with IBM-BMT + i.v.-DLI showed severe graft-versus-host disease 
      (GVHD), in contrast to those treated with IBM-BMT + IBM-DLI. The suppressive 
      activity of BMSCs in this GVHD model was determined. The cultured BMSCs from the 
      recipients treated with IBM-BMT + IBM-DLI suppressed the proliferation of 
      responder T cells remarkably when compared with those from the recipients of 
      IBM-BMT + i.v.-DLI in mixed leucocyte reaction. Furthermore, the level of 
      transforming growth factor-beta and hepatocyte growth factor in cultured BMSCs 
      from IBM-BMT + IBM-DLI increased significantly when compared with those from the 
      recipients of IBM-BMT + i.v.-DLI. Thus, the prevention of GVHD observed in the 
      recipients of IBM-BMT + IBM-DLI was attributable to the increased production of 
      immunosuppressive cytokines from BMSCs after interaction with host reactive T 
      cells (in DLI).
FAU - Miyake, T
AU  - Miyake T
AD  - First Department of Pathology, and Department of Surgery, Kansai Medical 
      University, Osaka, Japan.
FAU - Inaba, M
AU  - Inaba M
FAU - Fukui, J
AU  - Fukui J
FAU - Ueda, Y
AU  - Ueda Y
FAU - Hosaka, N
AU  - Hosaka N
FAU - Kamiyama, Y
AU  - Kamiyama Y
FAU - Ikehara, S
AU  - Ikehara S
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080225
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Interleukin-3)
RN  - 0 (Transforming Growth Factor beta)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - Bone Marrow Cells/immunology
MH  - Bone Marrow Transplantation/*methods
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - Coculture Techniques
MH  - Graft vs Host Disease/immunology/*prevention & control
MH  - Hepatocyte Growth Factor/biosynthesis
MH  - Immune Tolerance
MH  - Interferon-gamma/biosynthesis
MH  - Interleukin-3/biosynthesis
MH  - Lymphocyte Transfusion/*methods
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Stromal Cells/*immunology
MH  - T-Lymphocyte Subsets/immunology/transplantation
MH  - Transforming Growth Factor beta/biosynthesis
PMC - PMC2384073
EDAT- 2008/03/01 09:00
MHDA- 2008/05/13 09:00
PMCR- 2009/04/01
CRDT- 2008/03/01 09:00
PHST- 2008/03/01 09:00 [pubmed]
PHST- 2008/05/13 09:00 [medline]
PHST- 2008/03/01 09:00 [entrez]
PHST- 2009/04/01 00:00 [pmc-release]
AID - CEI3615 [pii]
AID - 10.1111/j.1365-2249.2008.03615.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2008 Apr;152(1):153-62. doi: 10.1111/j.1365-2249.2008.03615.x. 
      Epub 2008 Feb 25.